<SEC-DOCUMENT>0001628280-23-026411.txt : 20230801
<SEC-HEADER>0001628280-23-026411.hdr.sgml : 20230801
<ACCEPTANCE-DATETIME>20230801134646
ACCESSION NUMBER:		0001628280-23-026411
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230801
FILED AS OF DATE:		20230801
DATE AS OF CHANGE:		20230801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		231130904

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk07x31x2023.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i095517e3cea84325a338304c8eea4303_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of August, 2023.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">August 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="finalpressreleaseannouncin.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated July </a><a href="finalpressreleaseannouncin.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">31</a><a href="finalpressreleaseannouncin.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">, 2023</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="finalpressreleasepricingof.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated August 1, 2023</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>finalpressreleaseannouncin.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1dab3aa164b14975a8bc5ddbd4057c54_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:143px;margin-bottom:5pt;vertical-align:text-bottom;width:247px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CYBIN ANNOUNCES OVERNIGHT MARKETED PUBLIC OFFERING <br>OF UNITS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TORONTO - July 31, 2023 - Cybin Inc. (NYSE American&#58;CYBN) (NEO&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed public offering of units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at a price per Unit and for aggregate gross proceeds to be determined in the context of the market (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Unit will be comprised of one common share in the capital of the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Common Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Share purchase warrant (each whole Common Share purchase warrant, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The terms of the Warrants will be determined in the context of the market.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cantor Fitzgerald &#38; Co. is acting as the sole book-running manager for the Offering. A.G.P.&#47;Alliance Global Partners is acting as lead manager for the Offering.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The definitive Offering terms will be confirmed at the time of pricing pursuant to the terms of an underwriting agreement to be entered into between the Company and Cantor Fitzgerald &#38; Co. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The Offering is expected to close on or about August 4, 2023, or such other date as the Cantor Fitzgerald &#38; Co. and the Company may agree, and completion of the Offering will be subject to market and other customary conditions, including approval of the Neo Exchange Inc., now operating as Cboe Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company intends to use the net proceeds from the Offering for the progression of the Company&#8217;s CYB003 and CYB004 programs, and for general corporate and working capital purposes. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Units will be offered in each of the provinces of Canada, excluding Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in the United States, pursuant to a prospectus supplement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Prospectus Supplement will also be filed with the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021 in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. Prior to forming an investment decision, prospective investors should read the Base Shelf Prospectus and the documents incorporated by reference therein, including any marketing materials, which are available on the Company&#8217;s SEDAR profile available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sedarplus.ca</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Company&#8217;s EDGAR profile at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. When available, copies of the Prospectus Supplement and Base Shelf Prospectus may be obtained by contacting Cantor Fitzgerald &#38; Co., Attention&#58; Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, or by email at prospectus&#64;cantor.com. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Suspension of the Company&#8217;s Purchases under the LPC Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the context of arranging for Offering, on July 31, 2023, the Company provided notice to Lincoln Park Capital Fund (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LPC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of the Company&#8217;s intention to suspend purchases under its purchase agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) effective immediately. The Purchase Agreement was entered on May 30, 2023, allowing the Company to issue Common Shares with a value of up to US$30 million from treasury to LPC from time to time at the Company&#8217;s discretion for a period of up to 36 months. The sale of Common Shares under the Purchase Agreement was qualified under a prospectus supplement dated May 30, 2023 to the Base Shelf Prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">May Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Company sold a total of US$465,273 under the Purchase Agreement prior to the suspension of sales. No further Common Shares will be sold to LPC pursuant to the May Supplement. Subject to receipt of all necessary regulatory approvals, the Company intends to file a new supplement with respect to the Purchase Agreement to be filed under a new base shelf prospectus.&#160; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Cybin</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain statements in this press release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, &#8220;forward-looking statements&#8221;). All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#8217;s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;aim&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;would&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;forecast&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221; or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the anticipated closing of the Offering, the use of Offering proceeds, the receipt of applicable regulatory approvals, including the approval of the Exchange, the Company&#8217;s ability to relaunch sales under the LPC Agreement, and the Company&#8217;s ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statements. Such factors, among other things, include&#58; implications of the COVID-19 pandemic on the Company&#8217;s operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in the Company's management's discussion and analysis for the year ended March 31, 2023, the Company&#8217;s annual information form for the year ended March 31, 2023, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the SEC on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor &#38; Media Contact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gabriel Fahel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Legal Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">irteam&#64;cybin.com &#8211; or &#8211; media&#64;cybin.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>finalpressreleasepricingof.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i084ccdb2ab0348ae95dff5b631833b32_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:143px;margin-bottom:5pt;vertical-align:text-bottom;width:247px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CYBIN ANNOUNCES SIZE AND PRICING OF PREVIOUSLY ANNOUNCED </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TORONTO - August 1, 2023 - Cybin Inc. (NYSE American&#58;CYBN) (NEO&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cybin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight marketed public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of an aggregate of 24,264,706 units of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at a price of US$0.34 per Unit for aggregate gross proceeds of US$8,250,000.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Unit will be comprised of one common share in the capital of the Company (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Common Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Share purchase warrant (each whole Common Share purchase warrant, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Warrant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each Warrant will be exercisable to acquire one Common Share at a price of US$0.40 per Common Share for a period of 60 months.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cantor Fitzgerald &#38; Co. is acting as the sole book-running manager for the Offering. A.G.P.&#47;Alliance Global Partners is acting as lead manager for the Offering. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Offering is expected to close on or about August 4, 2023, or such other date as the Cantor Fitzgerald &#38; Co. and the Company may agree, and completion of the Offering will be subject to market and other customary conditions, including approval of the Neo Exchange Inc., now operating as Cboe Canada (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company intends to use the net proceeds from the Offering for the progression of the Company&#8217;s CYB003 and CYB004 programs, and for general corporate and working capital purposes. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Units will be offered in each of the provinces of Canada, excluding Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and in the United States, pursuant to a prospectus supplement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prospectus Supplement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the Company&#8217;s short form base shelf prospectus dated July 5, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Shelf Prospectus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Prospectus Supplement will also be filed with the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), as part of a registration statement on Form F-10, which was declared effective by the SEC on October 8, 2021 in accordance with the Multijurisdictional Disclosure System established between Canada and the United States. Prior to forming an investment decision, prospective investors should read the Base Shelf Prospectus and the documents incorporated by reference therein, including any marketing materials, which are available on the Company&#8217;s SEDAR profile available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sedar.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> and the Company&#8217;s EDGAR profile at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Copies of the Prospectus Supplement and Base Shelf Prospectus may be obtained by contacting Cantor Fitzgerald &#38; Co., Attention&#58; Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, or by email at prospectus&#64;cantor.com. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">This news release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any sale of the securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About Cybin</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cautionary Notes and Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain statements in this press release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, &#8220;forward-looking statements&#8221;). All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#8217;s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;aim&#8221;, &#8220;intend&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;would&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;forecast&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;seek&#8221;, &#8220;should&#8221; or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the anticipated closing of the Offering, the use of Offering proceeds, the receipt of applicable regulatory approvals, including the approval of the Exchange, and the Company&#8217;s ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include&#58; implications of the COVID-19 pandemic on the Company&#8217;s operations&#59; fluctuations in general macroeconomic conditions&#59; fluctuations in securities markets&#59; expectations regarding the size of the psychedelics market&#59; the ability of the Company to successfully achieve its business objectives&#59; plans for growth&#59; political, social and environmental uncertainties&#59; employee relations&#59; the presence of laws and regulations that may impose restrictions in the markets where the Company operates&#59; and the risk factors set out in the Company's management's discussion and analysis for the year ended March 31, 2023, the Company&#8217;s annual information form for the year ended March 31, 2023, and the Company's listing statement dated November 9, 2020, which are available under the Company's profile on www.sedar.com and with the SEC on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin makes no medical, treatment or health benefit claims about Cybin&#8217;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin&#8217;s performance and operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investor &#38; Media Contact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Gabriel Fahel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Legal Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cybin Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1-866-292-4601</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">irteam&#64;cybin.com &#8211; or &#8211; media&#64;cybin.com</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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M@6*$.!DX)[%G#II4'JG8W7<@V*.P4YN-9^Y3RF!P=WGJT4^)%?=YLY(F5>+
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M>;DL\Q6I&$\.SA*XD$8Q0CTKU.,P,+BV>'UV]/)OSH#HS4<G,4'\?W$"/SD
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MQX ]:.-,<'.E>!3M1Q1W(A]%150Z=R\<$TSI:=&'9P&F<NR7,6:;ZY1A3J:
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M,1T^";N/O+M@8(,5"AIX+N2 O7B=3U?+UX/-CN2@?)'/^O>3CO7SA!>OCG(
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ML00"V6];?'K$Q?W(^',@P,G'_GU,**(@!4TJ5&E I-G'2 &TQVS03J.0+.$
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M-2@IW20**?V@[ @.4)= VR*)OH.*BNE5/7<_D_$G0)J37YA^4;11*=;J0I!
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M\^> :2JPNEBKRM=.,H8%F9,'@)NS([$&.G9T>ZQP:2?+%WGN,!DR!@>9DP>
M>J7LT:D$+Y-]!B6MGRJD@MPQ,F0,%#(G#P+M=B[DB*_-=89JVIDR]![M5/$H
MQOV\#!F#ALS)@T'CJ99TK(8M,V PNU;&7$SQZJ!UX5J^<Y+Q+I Y>6!H-AJ%
K9#"\K::-,Q[C;(;:J):ON1^2(6,X^'\FP^6FWC4CM     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
